CRVO - NASDAQ

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%

HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.89M

EPS-2.0200

P/E Ratio-1.16

Earnings Date03/16/2026

43.08M

Assets

332%

3Y+14.0%

5Y+77.0%

10Y+1792.0%

3.88M

Total Liabilities

49%

3Y+33.0%

5Y-6.0%

10Y+67.0%

39.20M

Total Equity

431%

3Y+12.0%

5Y+95.0%

10Y-94284.0%

CervoMed Inc. Funding & Solvency Profile

CRVO · NASDAQ

Current Assets

Cash & Cash Equivalents9.00M

Net Receivables2.25M

Inventory0.00

Other Current Assets0.00

Total Current Assets43 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets0

Total Assets

43.08M

Financial Health Analysis

Current Ratio

11.11x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.10x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

39 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

CervoMed Inc. Balance Sheet

CRVO • NASDAQ

CervoMed Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006	Dec 2005
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	9M	7.8M	4.1M	37.3M	18.5M	14.2M	8M	8.9M	1.6M	2M	21.9M	255K	312.1K	98.4K	0.0	0.0	800.0	196.0	0.0	0.0
Short-Term Investments	29.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	38.9M	7.8M	4.1M	37.3M	18.5M	14.2M	8M	8.9M	1.6M	2M	21.9M	255K	312.1K	98.4K	0.0	0.0	800.0	196.0	0.0	0.0
Net Receivables	2.3M	915.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2K	71.9K	0.0	0.0	0.0	10.2K	0.0	0.0	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2K	0.0	0.0	0.0
Other Receivables	2.3M	915.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2K	71.9K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.7M	0.0	0.0	0.0	0.0	9.5K	9.5K	0.0	0.0
Prepaids	1.9M	1.3M	64.1K	510K	260.8K	472.5K	923.1K	769.9K	50.8K	45.9K	2.3M	2.7M	77.6K	87.5K	613.2K	4.3K	35.9K	0.0	0.0	0.0
Other Current Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7M	0.0	0.0	0.0	0.0	162.9K	178.2K	0.0	0.0
Total Current Assets	43.1M	10M	4.2M	37.8M	18.8M	14.6M	8.9M	9.7M	1.6M	2M	24.2M	3M	461.6K	186K	613.2K	4.3K	219.2K	187.9K	0.0	0.0
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	0.0	0.0	0.0	298.4K	499.4K	350.3K	460.7K	79.8K	52K	102.3K	11.3K	49K	78.1K	10.1K	1.8K	2.5K	12.9K	0.0	0.0
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9M	6.9M	0.0	12.1M	7.6M	1.9M	3M	1.1M	1.1M	1.1M	2.1M	0.0	0.0
Intangible Assets	0.0	0.0	0.0	0.0	8.6M	8.6M	0.0	0.0	0.0	6.4M	6.4M	7.7M	0.0	350.5K	2.3M	3M	4.1M	4.4M	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	8.6M	8.6M	0.0	6.9M	6.9M	6.4M	18.5M	15.3M	1.9M	3.4M	3.3M	4M	5.1M	6.5M	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	250K	0.0	0.0	0.0	0.0	0.0	212K	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	168K	437.3K	0.0	0.0	-6.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	7.8K	0.0	15.6K	15.8K	322.3K	8.9M	9.1M	8.9M	-6.5M	0.0	0.0	0.0	50K	1.6M	40.5K	0.0	0.0	0.0	0.0
Total Non-Current Assets	0.0	7.8K	0.0	15.6K	9M	9.6M	9.7M	16.5M	15.9M	233.5K	18.6M	15.3M	2M	3.5M	5M	4.3M	5.1M	6.5M	0.0	0.0
Total Assets	43.1M	10M	4.2M	37.8M	27.7M	24.3M	18.6M	26.1M	17.5M	2.3M	42.8M	18.3M	2.4M	3.7M	5.6M	4.3M	5.4M	6.7M	0.0	0.0
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.6M	782.9K	97.3K	947.5K	545.8K	1.3M	198.8K	512K	1.7M	424.7K	417.3K	1.7M	2.1M	973.2K	1M	1.3M	603.2K	622.4K	37.5K	10K
Accounts Payable	1.5M	662.5K	97.3K	947.5K	545.8K	1.3M	198.8K	512K	1.7M	424.7K	417.3K	1.5M	1.2M	789K	903.3K	385K	603.2K	622.4K	37.5K	10K
Other Payables	40.5K	120.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	156.4K	945.2K	184.2K	127.4K	910.6K	0.0	0.0	0.0	0.0
Accrued Expenses	1.4M	698.1K	593.9K	1.9M	1.7M	182.7K	409.9K	535.7K	399.7K	583.6K	1.8M	2.9M	1.8M	2.2M	1.7M	1.2M	1.1M	1.7M	30.5K	9.9K
Short Term Debt	0.0	0.0	12.4M	0.0	0.0	0.0	0.0	550K	1.9M	425K	0.0	1.9M	4M	555K	1.4M	150.3K	2.6M	1.5M	75K	75K
Capital Lease Obligations (Current)	0.0	0.0	0.0	0.0	113.5K	111.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	40.5K	120.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9K	0.0	0.0
Other Current Liabilities	919.1K	1.1M	50.3K	65.9K	35.4K	175.8K	195.3K	1.1M	474.5K	38K	99.2K	2.5M	12.9M	15.9M	814.3K	521.2K	0.0	2.8M	0.0	0.0
Total Current Liabilities	3.9M	2.6M	13.2M	2.9M	2.4M	1.7M	804K	2.7M	4.4M	1.5M	2.3M	8.9M	20.9M	19.7M	4.9M	3.2M	4.3M	6.6M	143K	94.9K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	550K	818.6K	0.0	0.0	0.0	0.0	625K	625K	625K	1M	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	443.9K	2.3M	2.2M	2.2M	3.3M	0.0	2.3M	3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	437.3K	1.4K	31.9K	28.3K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	0.0	0.0	0.0	0.0	479.6K	2.4M	2.2M	2.2M	3.9M	846.9K	2.3M	3M	0.0	0.0	625K	625K	625K	1M	0.0	0.0
Capital Lease Obligations	0.0	0.0	0.0	0.0	149.2K	135.6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	3.9M	2.6M	13.2M	2.9M	2.9M	4.1M	3M	4.9M	8.3M	2.3M	4.6M	11.9M	20.9M	19.7M	5.6M	3.8M	4.9M	7.6M	143K	94.9K
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	24.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.0	28.0	24.0	0.0	0.0	0.0	0.0	0.0
Common Stock	8.7K	5.7K	518.0	2K	64K	33.5K	3.4K	14.5K	10.3K	8.1K	18.6K	5.8K	891.0	88.2K	64.1K	58.6K	57.1K	49K	119.0	119.0
Additional Paid-In Capital	109.9M	61.8M	19M	164.9M	130.7M	111.8M	95.5M	82.8M	69.4M	42.1M	113.4M	67.4M	38.3M	33.3M	27.2M	18.5M	15.2M	9.8M	12.6M	12.6M
Retained Earnings	-70.7M	-54.4M	-52.3M	-130M	-105.9M	-91.7M	-79.9M	-61.6M	-60.2M	-42.2M	-75.3M	-60.9M	-56.7M	-49.4M	-26.5M	-18.1M	-14.7M	-10.8M	-12.7M	-12.7M
Accumulated Other Comprehensive Income/Loss	56.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.6K	0.0	0.0	0.0	0.0	0.0	0.0	-750K	0.0	-100K	0.0	0.0	0.0
Total Stockholders' Equity	39.2M	7.4M	-9M	34.9M	24.8M	20.1M	15.6M	21.2M	9.2M	-41.6K	38.2M	6.5M	-18.4M	-16M	20.2K	493.6K	439K	-905.9K	-143K	-94.9K
Total Equity	39.2M	7.4M	-9M	34.9M	24.8M	20.1M	15.6M	21.2M	9.2M	-41.6K	38.2M	6.5M	-18.4M	-16M	20.2K	493.6K	439K	-905.9K	-143K	-94.9K
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4K	-19.1K	30.8K	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	43.1M	10M	4.2M	37.8M	27.7M	24.3M	18.6M	26.1M	17.5M	2.3M	42.8M	18.3M	2.4M	3.7M	5.6M	4.3M	5.4M	6.7M	0.0	0.0
Total Investments	29.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	250K	0.0	0.0	0.0	0.0	0.0	212K	0.0	0.0	0.0	0.0
Total Debt	0.0	0.0	12.4M	0.0	149.2K	247K	0.0	550K	2.4M	1.2M	0.0	1.9M	4M	555K	2M	775.3K	3.2M	2.5M	75K	75K
Net Debt	-9M	-7.8M	8.3M	-37.3M	-18.4M	-13.9M	-8M	-8.3M	877.1K	-753.6K	-21.9M	1.6M	3.7M	456.6K	2M	775.3K	3.2M	2.5M	75K	75K
Shares Outstanding	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720	9,252,720

SEC Filings

CRVO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	January 08, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 05, 2025	December 01, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 07, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 29, 2025	October 27, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 22, 2025	October 22, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 08, 2025	October 08, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 11, 2025	August 11, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 08, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 411 filings

Related Guides

Blog Categories

Continue your CRVO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.